Minnesota temperature thank good us joining is XX where and afternoon, negative you for Tim, degrees. Thanks, the outside and from
well our coatings strategic balloon and IVD as fiscal We in offerings. to including execution in progress drug-coated great start initiatives, programs our XXXX our Medical as substantial a of the are off Device
In quite and our of in This be and proud quarter the of revenue agreement bottom generated at million we have to line entire revenue from of of growing team with They million, success. excellent performance XX% are we the Surmodics. instrumental accomplishments our our momentum Abbott. and continued growing reflect first first results top Our fiscal the of and XXXX. SurVeil included over quarter, X.X $XX.X been
We also reported per of $X.XX per first earnings share quarter. positive $X.XX diluted in the GAAP and share earnings of non-GAAP
fiscal quarter year, Looking the which we our in positioned to objectives our our we major have fiscal ahead, for strategic in Tim discuss building described the each XXXX. previously well that we of very XXXX our momentum were fiscal pleased expectations three first of the are In and will made later with revenue updated call. progress
are pivotal and reminder, to make achieving to progress enrollment first towards mark. CE SurVeil, these substantial As the study ensure success a of specifically TRANSCEND complete the to
and ongoing our revenue to to Medical our capital Second, platform initiatives. we on offerings non-drug continue IVD portfolio, to pipeline finally, flow advances device continue to significant And thrombectomy return and These drug-coated our development. existing meaningful including our growth and delivery acceleration coatings and fuel make of offerings. from with the provide invested growth drive balloon cash our cash and service Device flow strategic
core provide objectives. SurVeil. some on of me each color these Let Starting with
clinical this enrollment for halfway SurVeil. quarter sites for We of almost enrollment. acceleration the All of outside our and been U.S. point pivotal have takes are The United the trial beyond TRANSCEND, all States us the initiated. pleased total in well with the progress enrollment seat
European elements planned, notified filing obtain efforts to have of As to for the enrollment to the part we by TRANSCEND XXXX. as key mark regulatory CE of our SurVeil. expect end body complete our we fiscal Further, of our submitted
the changing Many we debate of of assumptions feedback nondrug we given has This devices receiving five in are a the recent controls Much the and following of than are end timing calendar no as on of later targeting the aware containing categories. While European of years. paper mark the are how the safety XXXX. There to that particular Meta-analysis regulations, paclitaxel to predict you triggered the devices described data publication sources significant it and analysis. such disagreement assumptions CE correct in the a analysis clinical involved is difficult methods significant use statistical Konstantinos pull industry category December of is much and from Greece. study. treat specific requires a limitations limitations multiple the and active Dr. debate of disparate were It drug-eluting in The the by on versus stents. increased vascular after a some in as paper created signal agent. including this paclitaxel to highlighted by applied balloons Katsanos pharmaceutical device the in made This meta-analysis the sophisticated devices closely. was of to and mortality as of and of three drug-coated whether intravascular and
and In demonstrated last data Dr. vigorously significant devices has available mortality. Physicians increase, Leaders not week discussion his of each in LINC Conference patient's earlier week's in VIVA addition, in level no this nor February mortality again and of Katsanos level contained relating continued data the the Surmodics where The sponsored at specific At the question These invited patient Group participate. Forum to difference to and be data on the at colleagues. to the presented at will Germany, was clinical by end were upcoming ISET discussed been and in the Meeting relevant information Florida rates. Vascular
continue committee continuing note events, data. these trial the steering as any the trial. is risk important It reporting a FDA with adverse TRANSCEND and to a In devices reduce included has supports the of that use and issued these the to at statement data notice continued recently they that current encourage surveillance the look that and of to benefit recommended addition, of the
to in is a area. safety TRANSCEND this with monitored this of clinical highly Our data is the trial reviewed steering leading will field. important independently and five-year comprised follow-up committee efficacy specific with world's clinicians expertise and rigorously
impact on have enrollment can of debate continue not and and into it seen clinical we We as a it will this result put where to fleet monitor an relevant.
are we other approval patient. to our initiate Turning the balloon. products pipeline, for in This we some first received promising that the arteriovenous and study successfully to drug-coated access AVess, treated is our exciting first have already in-human
by to track the trial first on of of are We end AVess the XXXX. calendar complete in-man
sirolimus this. in short, patients further satisfied is us we the preclinical with evolve will from last some based of set not formulations in-human we the regulatory complex the evaluations. results on on our innovated Moving coating improve drug earlier for and We of in the preclinical the we balloon, were initiate of we optimization In observed to submitting has the by and that and impact end disease believe and are and help achieve can intend that drug-coated delivery fiscal that on below-the-knee XXXX. trial favorable multi-factorial device the we these refining data most of studies for first Below-the-knee anticipate to process this. the to significant our approval
value. innovations work our additional We committed differentiated and clinical delivery in build highly of needs. that nondrug are innovations pipeline of solve also progress product help platforms to continue and the shareholder unmet us These to create will in next wave make to we
for approval XXXX X new X file During on to we fiscal remained regulatory on to submissions track devices.
of is difficult requiring these capable capital of often thrombosis development very requiring patient the excellent. Physician platform. is while of the surgery represents use of are table of removing to in design been simulated equipment Device design loss arterial reducing committed assets, and potential blood our We iteration Organized a minimizing of without and resulting to loss arterial hospitalization. in part hospitalization. thrombus our believe the thrombus a the blood we and As has thrombectomy solution model. accelerate patient first evaluation the on for an likelihood remove significant organized
submit all of As a not and months. approval Europe device anatomical to radial to world's end known for regular XX% disease patients. of radialists of by of its vascular of XX% sometime are access. for is that needs seek treat Radial devices the within ideas radial and are and we is safety and to The beds intend XX% The December, devices for the to on interventional We used thrombosis, approximately much will of than vasculature in bleeding application regulatory the of only lack next neurovascular practice and in a arterial to XXXX, better early healthcare In a treat infancy. group to and access in of femoral to fiscal peripheral artery the economics vessels for approval multiple the to models has is discussion the prototypes access for It a embolism first results complications U.S. intervention to given this the access limiting area. regulatory patient and the more in XX completion outcomes and peripheral seek Radialists Radial to for feedback access able time in develop time vessels the well in vascular fiscal to be thrombectomy low believe access were including to the radiologist We're for and potential develop however prefer XXXX. discharged generally treatment prison and seek pulmonary benefits -- interventions our we that impressed. faster access targeting the for factor. using coronary vascular top both coronary drive procedure. to in also our group a first risk the peripheral simulated but venous patients design quarter early thrombosis of versus and and reminder, for to radial artery the some arteries access for is activities convened approach surgeons who a radial able cardiologists, of peripheral was potential muscular applications. platform visibly physician and by This the test those following prototypes multiple thrombosis brought physicians,
strong across continued and growth Finally, Medical revenue seen execution by performance our superb product Device to categories. all businesses with IVD has produce
to mid that grow execution coatings Device the in business Medical to growth coatings continued excellent our segment credit the prior our digits contribute year. with the expiration. in expect business expected our have recent compared of It our the continue double-digit XXXX patent revenue such to to revenue derived team a in single to significantly fiscal modest in strength spite managed including coatings growth is We of in
growth. as and near With property, and intellectual XXXX our this team And the results relative our as as of second term looking the the IVD positioned across outlook over top continue now a half growing is although the details delivered accomplishments we to outperform XXXX. a are enhance provide and strength at quarter quarter, result performance this which weaker continues before. growth X%. performance stronger Our to business over first we quarter ever fiscal Tim of of our trajectory, immunoassay handily been more drive the comparison encouraged growth well the fundamentals to year. than also XX%. the operation business to are against last to call current as sum, turn for This market performance. past to fiscal exceptional assembled needed rates on revenue to team In elements Nevertheless, outlook our they've great significant breadth long the Tim. to are base performance customer well foundational I'll continued the the line by by well X% quarter
